四川省学术和技术带头人后备人选；中国生物医学工程学会肿瘤分子靶向治疗专业委员会秘书长/委员；中国抗癌协会肿瘤靶向治疗专业委员会委员；中国抗癌协会整合肿瘤分会委员；中国老年学和老年医学学会肿瘤康复分会委员；中国研究型医院学会分子肿瘤与免疫治疗专业委员会委员；北京癌症防治学会胃癌防治专委会委员等。

以第一作者/通讯作者发表多篇SCI论文（Trends in Cell Biol, Int J Cancer, Cancer Letters, FEBS Letters, Oncotarget），负责多项国家自然科学基金。如：Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data. Front. Pharmacol.2022 Glypican-3: A Novel and Promising Target for Treatment of Hepatocellular Carcinoma. Front Oncol. 2022 Feb 16;12:824208. Crosstalk between Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune-Checkpoint Inhibitors. Front Cell Dev Biol.2021 Oct 7;9:738373. A Distinct Clinicopathological Feature and Prognosis of Young Gastric Cancer Patients Aged ≤45 years. Front. Oncol. 2021 Aug 26;11:674224. Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Annals of Translational Medicine. 2021 Mar; 9(6): 513.